Searched for
CLINICAL STUDY PSORIASIS
How an Australian connection helped Shaily Mehrotra build a Rs 1,500-crore Indian skincare brandA gap in science-backed skincare products in the Indian market prompted Shaily Mehrotra to start Fixderma, with an aim to solve common skin...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma launches Ilumya for psoriasis treatment in IndiaSun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....
- Mankind gets CDSCO nod for Phase 1 clinical trials for molecule to treat autoimmune disordersMankind Pharma has received CDSCO approval to begin Phase 1 clinical trials for MKP11093, a molecule targeting multiple autoimmune disorder...
- Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trialsSun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for ...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- New psoriasis drug study yields positive results: Dr Reddy'sAccording to a press release from the city-based drug-maker, the detailed safety and efficacy data from the study would be presented in fut...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Almirall seeks nod for tildrakizumab in Europe: Sun PharmaThe filing includes efficacy and safety data from the pivotal Phase III clinical trials that included over 1,800 patients across more than ...
- Sun Pharma announces details of psoriasis drug trialsTildrakizumab is a monoclonal antibody designed to control the pathogenic cells responsible for the inflammatory process of psoriasis with ...
- Sun Pharma rises after licensing deal with AlmirallAt 11:01 am, shares of the company were trading at Rs 817.80 per share, up 1.24 per cent from its previous close on the Bombay Stock Exchan...
- Sun Pharma signs licening pact with spanish firm Almirall for psoriasis drugIn return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...
- GVK Bio extends partnership with Akaal PharmaGVK Bio has extended its tie-up with Australia's Akaal Pharma for scale-up of its novel topical AKP-11 ointment to support Phase II clinica...
- GVK Bio, Akaal Pharma extend partnership for drug developmentGVK Biosciences was under the regulatory scanner of European drug regulators a few months ago.
- Sun Pharmaceutical shares end nearly 2 per cent up on Merck & Co Inc licensing pactStock of the pharma firm settled with a gain of 1.63 per cent at Rs 805.20 on the BSE. During the day, it climbed 2.78 per cent to Rs 814.4...
- Sun Pharma signs pact with Merck; stock gainsTildrakizumab is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.
- Sun Pharma, Merck & Co Inc enter into pact for TildrakizumabUnder terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck.
- Nine new drugs under clinical stage: Dr Reddy'sAccording to a filing with US SEC, the drug maker said as of March 31, 2014, it had 20 active products in the proprietary products pipeline.
- Biocon seeking partners to develop, market psoriasis drugBiotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab
Load More
